DrugPatentWatch Database Preview
Details for Patent: 9,114,068
Which drugs does patent 9,114,068 protect, and when does it expire?
This patent has twenty-one patent family members in eight countries.
Summary for Patent: 9,114,068
Title: | Treating patients with intravenous ibuprofen |
Abstract: | Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure. |
Inventor(s): | Pavliv; Leo (Cary, NC), Rock; Amy Dix (Thompson Station, TN) |
Assignee: | Cumberland Pharmaceuticals, Inc. (Nashville, TN) |
Application Number: | 14/264,267 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 9,114,068
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL | ➤ Try a Free Trial | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 9,114,068
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,138,404 | Treating critically ill patients with intravenous ibuprofen | ➤ Try a Free Trial |
9,295,639 | Treating critically ill patients with intravenous ibuprofen | ➤ Try a Free Trial |
8,735,452 | Treating patients with intravenous ibuprofen | ➤ Try a Free Trial |
9,649,284 | Treating critically ill patients with intravenous ibuprofen | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 9,114,068
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2009350474 | ➤ Try a Free Trial | |||
Australia | 2010274030 | ➤ Try a Free Trial | |||
Brazil | PI0925034 | ➤ Try a Free Trial | |||
Canada | 2766367 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |